NCT02952885 (I-Con) is a Phase 3 clinical trial of Pegvisomant in Acromegaly, sponsored by Unity Health Toronto.

Who is sponsoring NCT02952885?

NCT02952885 is sponsored by Unity Health Toronto.

What drugs are being tested in NCT02952885?

Interventions in NCT02952885: Pegvisomant.

What condition does NCT02952885 study?

NCT02952885 studies Acromegaly.

Is NCT02952885 still recruiting?

NCT02952885 is currently completed. Last updated 22 November 2021.

Last reviewed 2021-11-22 · How we verify

NCT02952885: I-Con

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Strict IGF-1 Control in Acromegaly

Completed Phase 3 Last updated 22 November 2021

What this trial tests

Phase 3 trial testing Pegvisomant in Acromegaly in 10 participants. Completed in 7 May 2020.

Timeline

27 July 2017

Primary endpoint
7 May 2020

7 May 2020

Quick facts

Lead sponsor	Unity Health Toronto
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	27 July 2017
Primary completion	7 May 2020
Estimated completion	7 May 2020
Sites	5 locations across Canada

Drugs / interventions tested

Pegvisomant (PEGVISOMANT) — full drug profile →

Conditions studied

Acromegaly — all drugs for Acromegaly →

Sponsor

Unity Health Toronto — full company profile →

Who can join

18 and older, any sex, with Acromegaly. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acromegaly is a rare, chronic, and debilitating disease, usually caused by a benign tumor on the pituitary gland, which leads to excessive production of growth hormone (GH). GH excess in turn causes overproduction of another hormone called insulin-like growth factor-1 (IGF-1). IGF-1 levels are currently the most widely accepted measure of disease activity. In Canada, medical therapy with a type of medicine called "somatostatin analogues" (SSA), such as octreotide and lanreotide, is recommended for treatment of acromegaly. However, studies have shown that a significant number of patients who take SSA medications alone remain with elevated levels of IGF-1 in their blood. Another medication that is used to treat acromegaly is pegvisomant (PEGV), and the investigators plan to study whether strict control of IGF-1, by adding or optimizing the use of PEGV, results in a significant health benefits to patients who still have modestly high levels of IGF-1 in their blood.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

To what degree are orphan drugs patient-centered? A review of the current state of clinical research in rare diseases.
Lanar S, Acquadro C, Seaton J, Savre I, et al · · 2020 · cited 22× · PMID 32493385 · DOI 10.1186/s13023-020-01400-0
Impact of strict IGF1 control on quality-of-life scores in patients with acromegaly.
Gandhi C, Denis MC, Holmes D, Rivera J, et al · · 2025 · cited 1× · PMID 39959623 · DOI 10.3389/fendo.2025.1516899

Verify or expand the search:

Other trials of Pegvisomant

Trials testing the same drug.

NCT05470504 — Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance · Phase 2 · recruiting
NCT03882034 — Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess · Phase 3 · completed
NCT03225040 — Bone MicroArchitecture in Acromegaly · completed
NCT01538966 — Acromegaly Combination Treatment Study · NA · terminated

Other recruiting trials for Acromegaly

Currently open trials in the same condition.

NCT07037420 — ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly · Phase 2 · recruiting
NCT05401084 — Diet in the Management of Acromegaly · NA · recruiting
NCT05131100 — Korean Regulatory Post Marketing Surveillance for Somavert · recruiting
NCT05964712 — Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study · recruiting
NCT03158090 — The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research · recruiting

Other Unity Health Toronto trials

Trials by the same sponsor.

NCT07507409 — Innovative Sternal Closure Techniques: Evaluating STRATAFIX™ and DERMABOND™ for Reduced Complications in CABG Patients · Phase 4 · not yet recruiting
NCT07455487 — First Appendectomy Using Revolve Surgical Robotic Arm · NA · not yet recruiting
NCT07301632 — Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial · Phase 2 · recruiting
NCT07314905 — Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) · Phase 3 · not yet recruiting
NCT06571916 — Brief Skills for Safer Living (Brief-SfSL) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02952885 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Unity Health Toronto
Last refreshed: 22 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02952885.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing